Divi's Laboratories on Monday (9 March) said DCV-SEZ unit at Visakhapatnam started commercial production from 9 March 2020.
"This is to inform that the company has commenced commercial production effective from 9 March 2020 from DCV-SEZ unit of the company at Chippada Village, Bheemunipatnam Mandal, Visakhapatnam," Divi's Laboratories said in a statement.Divis Laboratories' consolidated net profit fell 7.8% to Rs 359.09 crore on a 2.7% rise in net sales to Rs 1,396.26 crore in Q3 December 2019 over Q3 December 2018.
Divi's Laboratories is engaged in manufacturing and sale of active pharmaceutical ingredients (APIs) and intermediates.
Shares of Divis Laboratories fell 3.58% at Rs 2,160. The scrip hovered in the range of Rs 2,141.05 to Rs 2,258 so far.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app